Sunshine Biopharma Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Sunshine Biopharma Inc. (SBFM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$2.18M.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.55M, a 200.48% decline year-over-year.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $1.54M.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.53M, a 122.77% decline year-over-year.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$1.42M.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$5.56M.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$6.01M, a 130.65% decline from fiscal 2022.
- Sunshine Biopharma Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $19.60M, a 1722.08% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.70M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$2.18M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$1.42M 10-K · filed 2026-04-03 | |||
| 2025-09-30 | -$477.26K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $293.30K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$1.55M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$5.56M 10-K · filed 2026-04-03 | |||
| 2024-09-30 | -$3.68M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$3.60M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $1.54M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$6.01M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | -$3.02M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | -$2.51M 10-Q/A · filed 2024-08-20 | |||
| 2023-03-31 | -$2.53M 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | $19.60M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $38.56M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $39.68M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $11.13M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $1.08M 10-K · filed 2023-04-04 | |||
| 2021-09-30 | $1.41M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $736.44K 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | $804.64K 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $949.76K 10-K · filed 2022-03-21 | |||
| 2020-09-30 | $449.22K 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $45.96K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |